Literature DB >> 30951022

Roseomonas gilardii Bacteremia in a Patient With HbSβ0-thalassemia: Clinical Implications and Literature Review.

Charles Schlappi1, Joshua D Bernstock2,3, Wilson Ricketts2, Garrett A Nix2, Claudette Poole4, Jeffrey Lebensburger1, Gregory K Friedman1.   

Abstract

Roseomonas gilardii is a Gram-negative coccobacillus identified in immunocompromised pediatric patients. A 5-year-old male with a history of HbSβ thalassemia status postsurgical splenectomy presented to the emergency department with fever. Blood cultures grew R. gilardii at 63 hours, but the patient had been discharged home at 48 hours. The patient was readmitted for repeat cultures and initiated on meropenem for 10 days as Roseomonas spp. are often resistant to third generation cephalosporins. R. gilardii is a rare cause of bacteremia in immunocompromised patients. Clinicians should consider Roseomonas in slow growing Gram-negative rod bacteremias, and consider meropenem as empiric coverage.

Entities:  

Mesh:

Year:  2020        PMID: 30951022      PMCID: PMC7724631          DOI: 10.1097/MPH.0000000000001476

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  19 in total

1.  Roseomonas mucosa isolated from bloodstream of pediatric patient.

Authors:  J Dien Bard; J G Deville; P H Summanen; M A Lewinski
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 2.  Infection in sickle cell disease: a review.

Authors:  Catherine Booth; Baba Inusa; Stephen K Obaro
Journal:  Int J Infect Dis       Date:  2009-06-03       Impact factor: 3.623

3.  Clinical characteristics of infections caused by Roseomonas species and antimicrobial susceptibilities of the isolates.

Authors:  Ching-Min Wang; Chih-Cheng Lai; Che-Kim Tan; Yu-Chuang Huang; Kuei-Pin Chung; Meng-Rui Lee; Kao-Pin Hwang; Po-Ren Hsueh
Journal:  Diagn Microbiol Infect Dis       Date:  2011-12-29       Impact factor: 2.803

Review 4.  Neutrophil dysfunctions in sickle cell disease.

Authors:  J R Humbert; E L Winsor; J M Githens; J B Schmitz
Journal:  Biomed Pharmacother       Date:  1990       Impact factor: 6.529

5.  Roseomonas gilardii infection: case report and review.

Authors:  Navkiran K Shokar; Gurjeet S Shokar; Jamal Islam; Alvah R Cass
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

6.  Outcomes of febrile events in pediatric patients with sickle cell anemia.

Authors:  Krishnaveni Sirigaddi; Inmaculada Aban; Amelia Jantz; Brandi M Pernell; Lee M Hilliard; Smita Bhatia; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

7.  Intestinal Salmonella carriage in patients with major sickle cell hemoglobinopathies.

Authors:  M B Rennels; J H Tenney; R E Luddy; M G Dunne
Journal:  South Med J       Date:  1985-03       Impact factor: 0.954

8.  Roseomonas, a new genus associated with bacteremia and other human infections.

Authors:  J D Rihs; D J Brenner; R E Weaver; A G Steigerwalt; D G Hollis; V L Yu
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

9.  Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil.

Authors:  Clarisse Lopes de Castro Lobo; Emilia Matos do Nascimento; Leonardo José Carvalho de Jesus; Thiago Gotelip de Freitas; Jocemir Ronaldo Lugon; Samir K Ballas
Journal:  Rev Bras Hematol Hemoter       Date:  2017-12-06

10.  Two Cases of Bacteremia Due to Roseomonas mucosa.

Authors:  Yu Kyung Kim; Jung Suk Moon; Kyung Eun Song; Won Kil Lee
Journal:  Ann Lab Med       Date:  2016-07       Impact factor: 3.464

View more
  1 in total

1.  Metagenomic Insights Into the Changes of Antibiotic Resistance and Pathogenicity Factor Pools Upon Thermophilic Composting of Human Excreta.

Authors:  Katharina A Werner; Dominik Schneider; Anja Poehlein; Nina Diederich; Lara Feyen; Katharina Axtmann; Tobias Hübner; Nicolas Brüggemann; Katharina Prost; Rolf Daniel; Elisabeth Grohmann
Journal:  Front Microbiol       Date:  2022-03-31       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.